We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+13.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$652M
AUM Growth
+$113M
Cap. Flow
+$93.9M
Cap. Flow %
14.4%
Top 10 Hldgs %
48.49%
Holding
247
New
47
Increased
63
Reduced
54
Closed
37

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$52.7M
2
PRTA icon
Prothena Corp
PRTA
+$25.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$13M
4
CYTK icon
Cytokinetics
CYTK
+$6.66M
5
SVRA icon
Savara
SVRA
+$6.09M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$16.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$8.17M
3
IMVT icon
Immunovant
IMVT
+$6.56M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.34M
5
AVR
Anteris Technologies
AVR
+$4.66M

Sector Composition

Rank Sector Weight
1 Healthcare 78.96%
2 Financials 2.75%
3 Consumer Staples 0.04%
4 Technology 0%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABOS icon
76
Acumen Pharmaceuticals
ABOS
$165M
$1.06M 0.16%
916,183
+770,000
+527% +$828K
CDTX
77
DELISTED
Cidara Therapeutics
CDTX
$1.05M 0.16%
21,522
+584
+3% +$14K
ZURA icon
78
Zura Bio
ZURA
$532M
$1.05M 0.16%
997,547
-1,803,637
-64% -$2.16M
BSAAU
79
BEST SPAC I Acquisition Corp Unit
BSAAU
$60.1M
$1M 0.15%
+100,000
New +$1M
ARGX icon
80
argenx
ARGX
$54B
$970K 0.15%
1,759
+1,159
+193% +$673K
MRUS
81
DELISTED
Merus
MRUS
$963K 0.15%
18,313
-48,647
-73% -$2.29M
ALDX icon
82
Aldeyra Therapeutics
ALDX
$96.5M
$957K 0.15%
249,920
+38,341
+18% +$99.1K
PFE icon
83
Pfizer
PFE
$145B
$955K 0.15%
39,400
-1,650
-4% -$38.5K
ARVN icon
84
Arvinas
ARVN
$548M
$948K 0.15%
128,767
-184,587
-59% -$1.36M
SRPT icon
85
CALL
Sarepta Therapeutics
SRPT
$1.72B
$941K 0.14%
+55,000
New +$2.35M
ACLX
86
DELISTED
Arcellx
ACLX
$919K 0.14%
13,962
– –
NKTR icon
87
PUT
Nektar Therapeutics
NKTR
$2.47B
$904K 0.14%
+35,000
New +$393K
NUVL
88
DELISTED
Nuvalent
NUVL
$904K 0.14%
+11,842
New +$866K
TENX icon
89
Tenax Therapeutics
TENX
$501M
$896K 0.14%
155,557
+86,816
+126% +$502K
SGRY icon
90
Surgery Partners
SGRY
$2.03B
$889K 0.14%
40,000
– –
ARWR icon
91
Arrowhead Research
ARWR
$12.5B
$872K 0.13%
55,200
-1,100
-2% -$15.8K
KRRO icon
92
Korro Bio
KRRO
$166M
$859K 0.13%
68,815
+100
+0.1% +$1.44K
KVAC
93
DELISTED
Keen Vision Acquisition Corp
KVAC
$853K 0.13%
+75,000
New +$847K
VTGN icon
94
VistaGen Therapeutics
VTGN
$11.9M
$842K 0.13%
420,765
– –
APGE icon
95
Apogee Therapeutics
APGE
$10.1B
$785K 0.12%
18,070
-86,783
-83% -$3.3M
WVE icon
96
Wave Life Sciences
WVE
$1.17B
$746K 0.11%
114,814
+91,714
+397% +$606K
KALA icon
97
KALA BIO
KALA
$14.6M
$713K 0.11%
2,997
-2,982
-50% -$582K
LRMR icon
98
Larimar Therapeutics
LRMR
$433M
$687K 0.11%
+237,605
New +$550K
RCKT icon
99
Rocket Pharmaceuticals
RCKT
$382M
$676K 0.1%
275,800
+34,000
+14% +$172K
KZR
100
DELISTED
Kezar Life Sciences
KZR
$675K 0.1%
147,404
– –
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, ADAR1 Capital Management held 247 positions worth $652M, up 21% from $539M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management deployed $93.9M of net new capital in Q2 2025, opening 47 new positions and adding to 63 existing holdings. Its largest new stake was Prothena Corp: 3,375,009 shares worth $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Roivant Sciences, an estimated $16.7M trimmed.

  • ADAR1 Capital Management's largest Q2 2025 buy was Prothena Corp: 3,375,009 shares worth $20.5M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q2 2025, an estimated $52.7M increase.
  • ADAR1 Capital Management's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $16.7M.
  • ADAR1 Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $652M portfolio in Q2 2025.
  • ADAR1 Capital Management opened 47 new positions and closed 37 in Q2 2025.
  • ADAR1 Capital Management's portfolio value rose 21% quarter-over-quarter to $652M.

Based on ADAR1 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.